|
**Overview**: KRAS Codon 12-13 Panel**Introduction**: The KRAS Codon 12-13 Panel is a diagnostic tool designed to detect KRAS mutations in codons 12/13 using FFPE tissue. In India, KRAS mutations in codons 12/13 are the most common (~35-45 percent in CRC, ~20-30 percent in lung adenocarcinoma), strongly predicting resistance to anti-EGFR monoclonal antibodies and guiding chemotherapy selection. High morbidity from under-testing in rural/low-SES advanced cancer patients, limited molecular pathology labs, delayed appropriate regimen leading to treatment failure or progression. Per oncology practices aligned with ICMR and Indian Society of Medical Oncology guidelines, the test employs PCR for KRAS codon 12 and 13 mutations over 1-2 days with high sensitivity, valuable for precision medicine in metastatic CRC and NSCLC. This diagnostic falls under genetic cancer screening and targets patients with advanced CRC or lung cancer, addressing accurate detection to avoid ineffective EGFR-targeted therapy and optimize treatment. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise mutation profiling and improving cancer survival. Its FFPE-based approach ensures reliable hotspot mutation detection.**Other Names**: KRAS 12/13 Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/oncology, compliant with 2025 standards.**Historical Milestone**: KRAS codon 12/13 testing standard in CRC since 2008; in India, routine in oncology.**Purpose**: The test assesses 2 parameters including KRAS Codon 12 mutation to guide mutation detection, predict therapy resistance, inform chemotherapy.**Test Parameters**: 1. KRAS Codon 12 Mutation, 2. KRAS Codon 13 Mutation.**Pretest Condition**: No fasting required; patients should have confirmed malignancy.**Specimen**: Formalin-fixed paraffin-embedded block (0.5â€"2 cm³), transported within specified times to maintain sample integrity.Sample Stability: Indefinite when properly stored in formalin/paraffin; testing possible long-term.**Medical History**: Patients should provide details on tumor type, stage, prior therapy.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected mutation including wrong therapy, benefits of profiling, and no additional discomfort (uses existing block).**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Poor block quality, inadequate tumor content, or interpretation differences can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive codon 12/13 mutation predicts EGFR inhibitor resistance, necessitating specialist input.**Specialist Consultation**: Medical oncologists should be consulted for management.**Additional Supporting Tests**: NRAS/BRAF, NGS for confirmation.**Test Limitations**: Detects only codons 12/13; comprehensive approach required.**References**: Indian Journal of Medical Oncology 2024, Cancer Studies India 2023. |
